Creation
Draft
Signpost/Archive
Idea Description
Supplementary Information
Innovation 'Elevator Pitch':
RespiraSense demonstrated a potential for 6-12 hours earlier detection of patient deterioration when compared to the standard of care. Putting that into context, for every 30-minute delay in treating Sepsis, increases the risk of mortality by 7%.
Overview of Innovation:
RespiraSense is the world's only continuous respiratory rate monitor. Respiratory rate is the earliest and single most sensitive indicator of patient deterioration, more so than heart rate if systolic blood pressure. In fact, 26 breaths per minute are considered the earliest point of divergence between Spo2 and respiratory rate. Giving rise to 12+hours of false security is accurate RR is not measured.

The standard of care remains the manual counting of breaths per minute, which has been shown to be biased and prone to error. With evidence showing no change in the quality of measurements for over 170 years (1846SirHutchenson) (2017Badawy).

RespiraSense gives medical teams the advantage of being able to intervene early, thus reducing time to intervention and improving outcomes. Outcomes such as Average Lenght of Stay, Average Unit Cost of Care, and Patient Safety targets can be achieved.

RespiraSense is a simple, wireless, and discrete wearable monitor, placed on at admission and worn/measuring continuously for upto 7 days. Each patient recieves a new sensor and a reusable electronic device or Lobe. See how the system works @
https://www.youtube.com/watch?v=u6KB1hBPQbM​
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
Similar Content3
Innovation 'Elevator Pitch':
RespiraSense demonstrated a potential for 6-12 hours earlier detection of patient deterioration when compared to the standard of care. Putting that into context, for every 30-minute delay in treating Sepsis, increases the risk of mortality by 7%
Overview of Innovation:
RespiraSense is the world's only continuous respiratory rate monitor. Respiratory rate is the earliest and single most sensitive indicator of patient deterioration, more so than heart rate if systolic blood pressure. In fact, 26 breaths per minute are considered the earliest point of divergence between Spo2 and respiratory rate. Giving rise to 12+hours of false security is accurate RR is not measured. 

The standard of care remains the manual counting of breaths per minute, which has been shown to be biased and prone to error. With evidence showing no change in the quality of measurements for over 170 years (1846SirHutchenson) (2017Badawy). 

RespiraSense gives medical teams the advantage of being able to intervene early, thus reducing time to intervention and improving outcomes. Outcomes such as Average Length of Stay, Average Unit Cost of Care, and Patient Safety targets can be achieved. 

RespiraSense is a simple, wireless, and discrete wearable monitor, placed on at admission and worn/measuring continuously for up to 7 days. Each patient receives a new sensor and a reusable electronic device or Lobe. See how the system works @ https://www.youtube.com/watch?v=u6KB1hBPQbM  
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Each year, there are approximately 500,000 admissions of Sepsis and Pneumonia with an average unit cost of £4,600 per admission. These two conditions are increasing in incidence and often lead to an escalation of care due to the risk of undetected deterioration. It's shown that a 5% reduction in the escalation of care of these two pathways alone, through the use of continuous Respiratory Rate monitoring triggering decreased time to interventions (Fluids, Oxygen, Antibiotics, Steroids), can reduce the average unit cost by £300 and the average length of stay by 0.5 days. This translates into a total Net cash saving of £115m and 250K bed days. Popular opinion suggests that as high as 20% reduction is achievable - Evidence pending. 

Each event prevented, having an average cost of £25,000, will pay for a whole year's supply of sensors for one year.
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
West Midlands Trusts are driving the awareness of Sepsis through their ambulance services, patient awareness campaigns, and in-hospital initiatives. With 44,000 lives lost each year attributed to Sepsis, it is important to Prevent, Diagnosis Early, and Effectively Treat the condition. RespiraSense focused on the area of Diagnosis Early. Research suggests that NEWS2 is a more sensitive indicator of deterioration due to Sepsis than QSOFA. Both of which have Respiratory Rate as a critical parameter to measure. There is clinical and economical value in monitoring this essential vital sign accurately and clear additional benefit to having it monitored continuously. RespiraSense achieves both with low impact of False alarm due to its innovative design, boasting advanced motion-tolerance. 
Current and planned activity: 
PMD Solutions is working with Nursing Times to launch an educational campaign on the clinical science and importance of respiratory rate monitoring in acute care clinical practice. 

In addition, PMD Solutions is looking for Respiratory and Emergency teams to partner with and create a culture of Peer Leadership in the development of best practice for respiratory rate monitoring. 
What is the intellectual property status of your innovation?:
RespiraSense is positioned to be the new industry standard in respiratory rate monitoring. It is patented in Europe, United States, China, Hong Kong, and Japan. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regulatory Approvals:
Please describe any current regulatory approvals you have achieved and how they were met/ in progress/planned.
Commercial information:
Please describe how the product/service is being developed commercially, whether in development, trials, pilot or full commercial delivery. Include the results you have from any market/demand surveys and forecasts . Please include any research you have on the broader commercial opportunity for the innovation both within the health sector nationally and internationally.
Investment activity:
Please describe what stage of investment you have reached and whether you are seeking additional rounds of investment. Please include cash investment as well as investment of soft assets such as access to specialist equipment, knowledge, trial base etc. and indicate the types/sources of your investment such as grants etc.
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Investment sought:
What investment are you looking for in order to support wider adoption of this innovation and what have you managed to secure to date? Please provide a breakdown of these costs if possible.
Read more
Hide details
Innovation 'Elevator Pitch':
Sensium Wireless Vitals Monitoring is proven to lead to treatment of sepsis 6 hours quicker than NEWS, reduce LOS by 10% and readmission by 45%. The only wearable vital sign monitor with peer reviewed RCT data showing significant clinical benefits. 
Overview of Innovation:
In general care areas of a hospital vital signs are typically taken during routine observation rounds once every 4-8 hours. If a patient deteriorates between these observation rounds the warning signs can go undetected for hours, potentially leading to serious & costly consequences. 
 
Sensium is a discreet, wearable, wireless system for monitoring vital signs of patients outside of high acuity areas. A light comfortable sensor worn on the patient’s chest accurately and reliably monitors and reports vital signs, providing data every 2 minutes. By notifying clinicians of changes in patients’ vital signs Sensium brings the nurse to the deteriorating patient, allowing intervention before the condition worsens, thereby improving patient outcomes, shortening hospital stays and lowering treatment costs. It enables nurses to prioritise patient care where it is needed most.   Sensium is focussed exclusively on general care clinicians whose patients currently do not have the safety and security of continuous vital sign monitoring.
 
The Sensium Patch provides accurate and continuous monitoring of the 3 key leading indicators of patient deterioration: heart rate (HR), respiration rate (RR) & axillary temperature (T). Sensium wirelessly communicates this physiological data via safe and secure low power wireless communication to the Sensium bridges placed through the ward area.  Sensium allows patients to ambulate freely, untethered to static and expensive equipment whilst still having the reassurance of continuous monitoring.
 
The bridges are connected into the hospital IT system, and software installed on the hospital network allows patient data to be seamlessly conveyed. Crucially, notifications can be configured to work with hospital pager systems/mobile notification devices, giving the clinical team data when they need it, where they need it. To save time and ensure accuracy Sensium can be easily integrated with the hospital admission, discharge, transfer systems and electronic medical records.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Currently approximately 10% of patients are harmed during their hospital stay and this represents a cost to the NHS of over £2.5bn just to cover the additional length of stay for these patients. Improved monitoring regimes and early detection of deterioration is key to reducing this significant burden.
 
Patients undergoing major abdominal surgery have an 30-40% risk of complications with a leading complication being sepsis. Hospital acquired (HA) sepsis (e.g. sepsis that develops after a surgical procedure) has twice the mortality rate and twice the treatment cost of community-acquired sepsis and rates of HA sepsis are rising. A recently-published study aimed to assess differences in outcomes between patients being monitored using the Sensium system in addition to intermittent (routine) observations and patients being monitored by routine observations alone [1].  The study was designed as a pilot cluster-randomised, prospective, parallel-group, controlled single-centre pilot study and consenting participants were allocated to one of two monitoring arms for the length of their admission. The primary outcome measure was time to antibiotics after the first evidence of sepsis, defined according to a revised consensus conference definition in 2001 [2]. Secondary outcome measures included length of hospital stay, 30-day readmission rate, mortality and patient acceptability. 226 patients were randomised between January and June 2017. 140 patients were randomised to continuous remote monitoring; 86 patients were randomised to receive intermittent monitoring alone. There were a similar number of complications and sepsis events across both arms of the study, indicating that both groups had similar baseline risk factors.

On average, patients receiving Sensium continuous monitoring were administered antibiotics 6.4 hours sooner after evidence of sepsis, had a 10% shorter average length of hospital stay and were 45% less likely to require readmission within 30 days of discharge than those patients in the intermittent monitoring group. Patients found the monitoring device to be acceptable in terms of comfort and perceived an enhanced sense of safety. Given that every hour’s delay in treatment of sepsis has been shown to be associated with a 7% increase in risk of mortality [3], a 6-hour reduction in time to administer antibiotics is a significant result and further studies are ongoing to demonstrate similar benefits in other clinical settings.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Sensium’s solution offers several key benefits to the West Midlands and its population. The key benefits of Sensium compared to competitor products are as follows:

Product Performance: Sensium uses clinically accepted ‘gold standard’ methods of vital sign measurement, deriving heart rate from single-lead ECG, respiration rate from thoracic impedance, and temperature from an axilla sensor.  In contrast, our competitors derive respiratory rate from pulse or ECG measurements which has known limitations in certain clinical conditions and provide only skin temperature measurement which has limited clinical value.

Customer Focus: Sensium is recognised by our customers for exceptional customer support.  Once we deploy our product at a clinical site, we provide on-site technical support for installation and troubleshooting and clinical support for training for as long as it takes for the system to be truly embedded in the clinical workflow and providing tangible benefits. Sensium has clinical and technical staff based in the West Midlands region on hand for support.

Clinical Evidence: Sensium understand that medicine is an evidence-based science and we are engaged in a series of clinical research studies designed to show clinical efficacy, improved clinical outcomes, and health economic benefits.  To date, Sensium are the only company providing wearable wireless technology for early detection of patient deterioration that have independent and peer-reviewed publications showing benefits of our technology demonstrated through randomised controlled trials
 
 
Current and planned activity: 
Our initial engagement with the NHS has been to introduce Sensium to general surgery wards and areas with high risk and infection prone patients e.g. colorectal, trauma and haematology wards. Discussions with many NHS hospitals have also shown significant interest and benefit for the use of Sensium for ‘Step down’ areas for patients who aren’t sick enough for ITU but still show cause for concern and for high risk conditions such as Hospital Acquired Sepsis opioid depression and AF. 

We have engaged with the Emergency Laparotomy Collaborative with a view to patch these types of patients. When approaching the NHS, we have been primarily engaging with Anaesthetists as they witness many patient deteriorations, as well as consultants and sepsis/patient deterioration leads, matrons and clinical IT leads. We plan to interact more directly with medical directors and members of the directorate earlier on in the process if possible. Future plans include home monitoring to follow patients’ home.
What is the intellectual property status of your innovation?:
CE mark and FDA 510(k) cleared.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
N/A
Ease of scalability: 
2
Co-Authors:
Read more
Hide details
Innovation 'Elevator Pitch':
Protect people with dementia from unattended falls, dehydration, malnutrition and hypothermia by hourly checking patterns of normal activities in their kitchens. 
Overview of Innovation:
Many older people want to live independently for as long as possible, causing anxiety for family and friends.  They are often in denial of their declining capacity, proud and won’t wear pendants.  With impaired cognition, many suffer from unattended falls, dehydration, malnutrition or hypothermia.  They are admitted to hospital needing longer treatment for poorer health outcomes and greater risk of transfer into a care home. 

To make sure that service users are moving around as normal, drinking, eating and warm, Kemuri checks every hour.  It alerts families and carers of important changes and provides valuable details for guiding action.  Peace of mind results in better outcomes and reduced costs for everybody.

Kemuri does not stigmatise because it looks a familiar Power Socket to the service user.  There’s nothing to remember and people continue with normal activities such as boiling kettles and heating food in microwaves or other electrical equipment.


KemuriSense® mains Smart Power Sockets continuously monitor motion, power usage, temperature and humidity and send data via GSM mobile phone signals to the Internet.  Mains power loss is automatically reported whilst it continues to report other sensor readings.  

The Wellbeing Monitor App informs families and carers of older vulnerable people who:
  • Want to live independently
  • Reject or forget pendant alarms
  • Deny declining capacity
  • Show symptoms of dementia
  • Remove things they don’t understand
  • Need daily monitoring 


Predictive analytics check every hour for changes to patterns of motion and power usage.  If there are many changes, then alerts may be sent to families, carers or 24/7 response centres.

As stated by a Commissioning Manager at a County Council, “ ... this is a unique product ….  I think there’s potential here for both self funder and LA funding as a potential option that fills a gap that conventional telecare does not.”
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health
Benefit to NHS:
Dementia is increasing in the population. Kemuri is a tool for stabilising the wellbeing of older people living alone who are declining in their ability to undertake Activities of Daily Living. Better wellbeing means healthier people, better health outcomes & more efficient use of NHS resources. Institute of Ageing research shows a range of pathways that people take before they are unable to live independently.


Early intervention is proven to reduce costs significantly. Kemuri should be deployed as soon as people are showing early symptoms of dementia. With loss in mobility, falls are inevitable: half those 80+ fall at least once p.a. Falls cost the NHS £2bn p.a. People with dementia tend to forget their pendant alarms/wearable telecare devices. If unable to call for help they may suffer for days before discovery & admission to A&E with medical complications. Kemuri’s hourly analysis of patterns of motion power usage automatically alerts to the risk of unattended falls.

In comparison pendant alarms are ineffective with early stage dementia. Out of 1.6m issued 32% are never worn & only 8% are worn all the time as prescribed. 500,000 unworn pendant alarms waste as much as £80m p.a. Kemuri continuously monitors motion, learns patterns of activity without any cognitive input from the service user.


A value to the NHS of early A&E admission into hospital is better health outcomes & more people discharged back to independent living on average after 12.3 days (discharge to residential care on average 31.7 days, 2.5 times longer).



£5000 could be re-allocated for each episode avoiding discharge to a care home. Unattended falls longer than 24 hours result in stabilisation time, longer treatment & delayed transfers of care. Kemuri preventive telecare with a wellbeing monitor & daily attention will also help to minimise the number of patients suffering the effects of hypothermia, dehydration & malnutrition.
  • Cold homes cost the NHS in England more than £1.36bn p.a.
  • Dehydration complications include low blood pressure, weakness, dizziness, increased risk of falls, & pressure sores
  • Malnutrition costs the NHS £7bn p.a. Risk (in 2010) was 28% in patients < 60 years, 32% 60-79 years & 44% if > 80 years
Kemuri could be funded by the NHS for a few weeks after discharge on the grounds that people admitted in a healthier state are less complex to treat, have improved health outcomes & are less likely to be readmitted, with the ongoing service funded by Social Services or self-funders.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
West Midlands has a population of 5.6 million people covering an area of more than 5,000 square miles.  It is a region full of contrasts and diversity.  It includes the second largest urban area in the country (Birmingham, Solihull and the Black Country) yet over 80% of the area is rural.  It is the second most ethnically diverse region in the country after London.  There are probably 40,000 older people who might be suitable for passive wellbeing monitoring.  Many of these are admitted to hospital and may not be able to return to their own homes. 

Older people are at the focus of Kemuri wellbeing monitoring.  Hourly and daily pattern analysis reduces risk and extends the period that they can continue to live independently at home.  Everybody has access to information that reduces the risk of unattended falls, dehydration, malnutrition and hypothermia.  Alerts are automatic without older people having to change their life style.  A familiar power socket is not stigmatising or intrusive.  There are no wearable devices to remember or unfamiliar sensors to be discarded.  Discharge from hospital could be accelerated with a KemuriSense Power Socket pre-installed.

Families and carers use the Wellbeing App for peace of mind.  At any time of day, from anywhere in the World, people can view the changes to patterns of behaviour.  There’s an option to receive alerts after more changes than usual.  They can enquire about wellbeing with full knowledge of the predictive analysis and decide on appropriate action. Some of the tragic outcomes of unattended falls are avoidable with hourly monitoring.  Additionally, it’s possible to confirm that domiciliary carers have provided drinks and meals at the time they were ordered.

Service organisations benefit from accurate data.  Sheltered housing wardens, domiciliary care providers and alarm response centres have full access to the Wellbeing Monitor and can prioritise their care calls.  Kemuri is efficient to deploy.  The portable model is operational in ten seconds with no skill required.  The fixed model can be installed and tested within 15 minutes.  There are no rules to enter because the system learns patterns of activity.  Alerts are automatically sent to response centres or users of the app.  
Current and planned activity: 
Manufacturing batches of 100 units for trials/sales to housing associations/telecare service providers. First trials are in sheltered accommodation in County Durham in conjunction with Durham University (part of EU funded Erasmus+ project)

Controlled clinical trials required to collect evidence to support the benefits claimed (reducing impact of falls). Sample sizes to account for significant number of subjects continuing to live normally without any falls requiring intervention. Access to medical records/cost of treatment/health outcomes/discharge data/subsequent care pathways required

Kemuri collects accurate lifestyle data that can be used in clinical trials of drugs dispensed to people living independently including people with cognitive impairment/physical disability not able to record times of events/ambient conditions. KemuriSense power sockets can collect data for several years, in dementia trials it may be possible to identify rates of decline & use it to modify the care regime
What is the intellectual property status of your innovation?:
Kemuri has patents pending; GB1417259.7, effective date of 30 September 2014 and PCT/GB2015/000275, International Filing Date of 30 September 2015. 

Note that the patent applies to more devices than a power socket.  It covers the internal electronics and components, which could be incorporated into any equipment consuming significant amounts of power. 

Kemuri and KemuriSense are registered trademarks.  
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
3
Regulatory Approvals:
The KemuriSense Smart Power Socket has been tested for EMC (Electro Magnetic Compliance) and CE certification. 

The product only measures ambient conditions and does not require certification as a medical device.
Commercial information:
We are building batches of 100 for field trials with availability in January 2017. 

The projected sales shown in the table below.



The growth accelerates as more telecare resellers become customers.

Current and potential telecare users: The Strategic Society Centre undertook a major quantitative research project entitled Who uses telecare? published in 2012 to explore usage of telecare among older people in England and identify potential users of telecare. It provided a conservative estimate based on 2008 data that among the over-50s in England, there were well over 1 million telecare users. However, by mapping individuals with similar conditions, the report was able to identify around 2.5 million more individuals living alone who may be able to benefit from telecare, and potentially as many as 4.1 million with conditions that could merit the use of telecare.

Further, the report stated that around 30% to 50 % of current telecare users paid for their telecare themselves or with the help of a family member. Among private and non-privately funded telecare users, it appears there is little difference in incomes. This suggests that relatively low income is not a barrier to individuals and their families funding telecare themselves or that most users can contribute to the cost of telecare support.
The report made recommendations to policymakers to aim to boost the usage of telecare to at least double current prevalence focusing on individuals living alone. It also recommended that policymakers and the industry should focus on targeting informal carers, including both cohabiting and non-cohabiting family carers as potential beneficiaries of greater usage of telecare.

Global telecare market: The global telecare market is valued at c. £1 billion per annum and is forecast by the Deloitte Centre for Health Solutions to grow at a rate of 5% per annum from now to 2018. The factors contributing to growth and market attractiveness are related to government initiatives and funding and the public willingness and receptivity towards technological advancement. The UK is the leading market for telecare products and services, with the UK telecare market share of up to 25% of the global market. Other prominent markets for telecare in terms of ageing populations that demand such services include France, Italy and Benelux (comprising Belgium, Luxemburg and the Netherlands).

Ireland, Malta, Singapore, Hong-Kong, Malaysia and Saudi Arabia as potential overseas markets for KemuriSense®, as those territories use British standard socket outlets.
Investment activity:
Kemuri was founded by Dr Leonard Anderson, Russell Anderson and Michael Anderson in January 2014.  Together, they worked on the concept for an older person’s carer assistance solution after failing to find a suitable product and service on the market.  The Company’s activity to date has been focused on product and web-services development and has been funded from private and public sources.  Kemuri’s proof-of-concept project was successfully completed in October 2015, assisted by grants from Innovate UK; £66,734 for a Smart Grant and £5,000 for a Smart Voucher. A £2,000 prize from Kent County Council paid for the first smart power socket prototype. 

Dr Anderson has provided an unsecured director's loan facility of £100,000.

Innovate UK sponsored £5000 research with the Institute of Ageing at Newcastle University for the Ethics of Passive Monitoring.

The company raised £545,000 in a private offer via West Hill Capital.  The funds are being deployed to refine the core product infrastructure, to develop the mobile app, to recruit staff across operations and to build an online sales platform. 

Kemuri has been awarded with €100,000 as a partner in an Erasmus + project for people-centred centred design.  Our UK partner is Durham University together with others in Netherlands, Czech Republic and Slovenia

The Company is a growth business and will not be cash generative in the short term as it invests heavily in developing the business in order to generate long-term profitable business relationships.

A key requirement is to find funding for an academic study to collect evidence for the value of predictive analytics for a period of at least one year.  Grants are being sought from multiple sources.
Regional Scalability:
Smart power socket production is scalable (batches of 100-1000 p.m) in the Woking production facility (larger volumes achieved by second sourcing manufacture). The Web technology is cloud-based & can be rapidly scaled by commissioning more servers/storage at short notice. WM scale-up can be generated by raising awareness with the following:
  • Social Services Commissioners/OTs
  • GP Surgeries, Mental Health & Hospital Trusts
  • Housing Associations & Voluntary Sector eg AgeUK
  • Telecare Service Companies
  • Local media/online sales websites 
Welbeing, our telecare service partner’s clients include WM local authorities & housing associations, providing installation & call monitoring services to any new customers in the region.

As a start-up our effort is directed to delivering reliable hardware & software with small sample numbers. Our design objective is for KemuriSense power sockets to operate continuously for at least 5 years. First trials have started in County Durham housing associations.
Measures:
In co-operation with an academic research partner, we hope to achieve the following in a trial:

Quality
  • Continuous reliable operation
  • Avoidance of false alerts
  • Recognising unattended falls, strokes or other episodes that result in a carer taking action that saved time and cost for medical intervention.
  • Peace of mind achieved for families and carers
  • Identifying trends that indicate the risk of hypothermia, dehydration and malnutrition.
  • Identifying activity at unusual times of day that lead to helpful family or medical intervention 
Safety
  • Electrical safety of products after installation in kitchens.
  • Security of personal data and avoidance of data loss. 
Cost
The trial budget is £500,000.  This would include the costs of selection, installation, monitoring, service support and surveying families throughout the trial.  Note that his includes detailed data analysis, medical services, the final report and communications.
 
People
The target group for research is a cohort that has these attributes:
  • Reject pendant alarms
  • Deny declining capacity
  • Want to live independently
  • Show symptoms of dementia
  • Need daily monitoring
A percentage will be used as a control group who are not included in the Trial.  The total numbers are to agreed by the academic research partner from one of the West Midlands universities.
 
Ethics
Finding volunteer older people and their next of kin will require access to the medical records and adult social care records of older people living alone.  This will also be needed during the trial to measure the times and costs of medical treatment.  Approval by the Ethics Committee will be required.  
Adoption target:
Assuming that there are 500,000 unused pendants in the UK, there are approximately 40,000 candidates for Kemuri wellbeing monitoring in a West Midlands population of 5 million.   

500 is a reasonable target for 2017/2018 – with an possibility of growing to 10,000 in 5 years.  
Investment sought:
A total investment of £500,000 over two years would provide a trial that provides evidence for wider adoption in the Region.  For budgeting purposes, this breaks down as follows:
  • £40,000 - Project Management
  • £100,000 – Installation and Web services for 120 older people and their families
  • £50,000 – Health service costs
  • £250,000 – Academic research costs
  • £60,000 – Kemuri cost to support the trial. 
The findings should be applicable throughout the UK. 

The objective is to obtain SBRI funding for the project.  
Read more
Hide details
0
0
Votes

Created by

Share and Follow